Description
AOD 9604, also known as Advanced Obesity Drug 9604, is a synthetic peptide fragment derived from the C-terminus of human growth hormone (HGH). This peptide comprises amino acids 177-191 and is specifically designed to stimulate the breakdown of fat while avoiding the adverse effects associated with full-length HGH. Due to its targeted action, AOD 9604 has garnered significant interest in the fields of weight management and metabolic research.
Mechanism of Action
AOD 9604 works by mimicking the fat-reducing activity of natural human growth hormone. It activates the beta-3 adrenergic receptors, promoting lipolysis (the breakdown of fat) and inhibiting lipogenesis (the transformation of non-fat materials into body fat). Unlike full-length HGH, AOD 9604 does not cause hyperglycemia (increased blood sugar levels) or induce the growth of long bones, making it a safer option for weight loss and body composition improvement.
Benefits and Uses
- Fat Reduction: AOD 9604 has been shown to enhance the natural fat-burning process, making it an effective tool for reducing body fat, particularly stubborn adipose tissue.
- Metabolic Regulation: By promoting lipolysis and inhibiting lipogenesis, AOD 9604 helps in maintaining a balanced metabolism.
- Safety Profile: The peptide does not interfere with insulin sensitivity or increase blood glucose levels, distinguishing it from other weight-loss agents.
- Non-GH Related Effects: It provides the benefits of HGH related to fat loss without influencing growth or other HGH-mediated functions.
Clinical Research
Research on AOD 9604 has demonstrated its efficacy in animal models and human clinical trials. Studies have reported significant reductions in body fat and improvements in lipid profiles without adverse effects on insulin levels or cardiovascular health. These findings suggest that AOD 9604 is a promising candidate for obesity treatment and metabolic health improvement.
